BioXcel Therapeutics Inc. (NASDAQ: BTAI) Stock Information | RedChip

BioXcel Therapeutics Inc. (NASDAQ: BTAI)


$0.3299
+0.0145 ( +9.24% ) 527.8K

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Market Data


Open


$0.3299

Previous close


$0.3154

Volume


527.8K

Market cap


$15.48M

Day range


$0.2890 - $0.3330

52 week range


$0.2890 - $4.1700

SEC Filings


Form Type Description Pages Date
8-k 8K-related 20 Nov 25, 2024
8-k 8K-related 16 Nov 21, 2024
8-k 8K-related 14 Nov 14, 2024
10-q Quarterly Reports 88 Nov 14, 2024
8-k 8K-related 15 Oct 09, 2024
4 Insider transactions 1 Oct 03, 2024
4 Insider transactions 1 Oct 03, 2024
4 Insider transactions 1 Oct 03, 2024
4 Insider transactions 1 Oct 03, 2024
4 Insider transactions 1 Oct 03, 2024

Latest News